
Global Point-of-Care Glucose Testing Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
-
15656
-
Upcoming
-
NA
-
PDF
-
find_in_page Our Research Methodology is based on the following main points:
- Data Collections and Interpretation
- Analysis
- Data Validation
- Final Projections and Conclusion
- notifications
-
“Global Point-of-Care Glucose Testing Market” is an upcoming report by MarketResearch.biz. The global point-of-care glucose testing market segmentation allows for deeper understanding and thought, to decisively assess, study, and analyze. The study and analysis will be conducted using expert opinions and inputs, as well as comprehensive primary and secondary research efforts to determine various aspects of the point-of-care glucose testing market. Besides revenues for segments, global, regional, and country-wise market revenue segmentation will be compiled in a scrupulous manner for clear flow and understanding. The global point-of-care glucose testing market report will be segmented on the basis of product outlook, and region.
Overview:
Point-of-care testing or POCT, also known as extra laboratory or near-patient testing can be defined as medical diagnostic testing which is performed at the site of or near the patient with the result leading to a change in the care of the patient.
The escalating prevalence of diabetes around the world in recent times has put significant pressure on the healthcare system to manage these patients in a better way. This can be chalked up to the fact that diabetic patients are far more susceptible to ailments such as cardiovascular disorders, blindness, nerve damage, kidney failure, among others.
Dynamics:
The global point-of-care glucose testing market is anticipated to grow at a steadily higher CAGR than what was indexed in 2018. The increased rapidity in the diagnosis workflow when compared to other medical settings is what is expected to further help contribute to the growth of the global point-of-care glucose testing market over the next few years.
The initiation of favorable regulatory prices focused on the promotion of point-of-care glucose testing is anticipated to influence the market in a big way. Blossoming monitoring technologies such as standalone monitoring devices are set to boost the growth of the market. The increasing incorporation of data management programs in the monitoring of glucose has manifested in the improvement of diabetes therapeutics, resulting in better patient care and satisfaction.
Point-of-care monitoring devices allow for the self-monitoring of glucose levels at home. This allows the patient to perform routine day-to-day activities with relative ease. The i-STAT device segment generated the highest revenue share of the market in comparison to the other available devices. This is due to its multi-utility applications of this product. However, the Accu-chek Inform II meter generated the highest revenue in 2018 and is anticipated to continue its dominance over the forecasted period.
Regional Analysis:
With respect to the regional segmentation of the market, North America accounted for the largest revenue share of the global point-of-care glucose testing market in 2018 and is slated to maintain its position over the foreseeable future. Factors that are expected to fuel the growth of the Asia Pacific market is the higher prevalence of diabetes and a surging development of healthcare infrastructure.
Moreover, the increase in the adoption of miniaturized device models which help reduce the time spent in hospitals or clinics is expected to surge the demand for glucose POC testing devices, making the Asia Pacific the quickest growing region.
Global Market Segmentation:
Global market segmentation, by product outlook:
- Accu Check Aviva Meter
- Onetouch Verio Flex
- i-STAT
- Bayer CONTOUR blood glucose monitoring system
- Freestyle Lite
- True Metrix
- Accu-Chek Inform II
- StatStrip
Global market segmentation, by region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region - North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$ -
- Hoffmann-La Roche Ltd.
- Abbott, Nipro
- Nova Biomedical
- ACON Laboratories Inc.
- Trividia Health Inc.
- Prodigy Diabetes Care LLC
- Bayer AG/Ascensia Diabetes Care Holdings AG
- EKF Diagnostics
-
Request for TOC
-
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!